Atorvastatin calcium plus amlodipine for the treatment of hypertension

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 18, 2012, Pages 2673-2685

  Delgado Montero, Antonia ^a   Zamorano, Jose L ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Adherence; Cardiovascular risk; Dyslipemia; Hypertension; Single pill amlodipine atorvastatin

Indexed keywords

AMINOTRANSFERASE; AMLODIPINE; AMLODIPINE PLUS ATORVASTATIN; ATORVASTATIN; CALCIUM ION; CHOLESTEROL; DIHYDROPYRIDINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR;

ANGINA PECTORIS; AQUEOUS SOLUTION; ARTICLE; ASTHMA; BLOOD PRESSURE REGULATION; CALCIUM TRANSPORT; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CONJUNCTIVITIS; CORONARY ARTERY SPASM; COUGHING; DOSE RESPONSE; DRUG ABSORPTION; DRUG BINDING SITE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; EDEMA; ENZYME INHIBITION; EPISTAXIS; FLUSHING; HEART FAILURE; HEART LEFT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HEART MUSCLE CELL; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOTENSION; IMPOTENCE; LIPOLYSIS; LIPOPROTEIN BLOOD LEVEL; LIVER DISEASE; MOLECULAR WEIGHT; MUSCLE CRAMP; MYALGIA; NERVOUSNESS; NOCTURIA; PATIENT COMPLIANCE; PH; PHASE 4 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PREGNANCY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHABDOMYOLYSIS; SHOCK; SIDE EFFECT; SMOOTH MUSCLE; STEADY STATE; TRANSIENT ISCHEMIC ATTACK; UNSPECIFIED SIDE EFFECT; VASCULAR RESISTANCE;

AMLODIPINE; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; DRUG COMBINATIONS; DYSLIPIDEMIAS; EVIDENCE-BASED MEDICINE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; PYRROLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 84870222983     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.742064     Document Type: Article

References (91)

1. Levi F, Chatenoud L, Bertuccio P, et al. Mortality from cardiovascular and cerebrovascular diseases in Europe and other areas of the world: an update. Eur J Cardiovasc Prev Rehabil 2009;16:333-50
2. Battleman DS, Peterson ED. Estimated prevalence of comorbid hypertension and dyslipidemia and therapeutic goal attainment among US adults in 2000, utilizing datafrom the National Health and Nutrition Examination Survey (NHANES III). J Manag Care Pharm 2004;10:186
3. Neaton JD, Blackburn H, Jacobs D, et al. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Arch Intern Med 1992;152:1490-500
4. Thomas F, Bean K, Guize L, et al. Combined effects of systolic blood pressure and serum cholesterol on cardiovascular mortality in young (< 55 years) men and women Eur Heart J 2002 23 528-35
5. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97(18):1837-47
6. Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987-1003
7. Mancia G, De Baker G, Dominiczak A, et al. Guias de practica clinica para el tratamiento de la hipertension arterial. Rev Esp Cardiol 2007;60:968e1-e94
8. Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur J Prev Cardiol 2012;19(4):585-667
9. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997;157:2413-46
10. Chobanian AV, Bakris GL, Blac HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report. JAMA 2003;289:2560-72
11. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421
12. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39
13. Emberson J, Whincup P, Morris R, et al. Evaluating the impact of population and high-risk strategies for the primary prevention of cardiovascular disease. Eur Heart J 2004;25:484-91
14. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOTLLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-58
15. Pettitt D, Karter AJ, Peng TY, et al. The impact of concurrent dyslipidemia and diabetes on hypertension management and goal attainment. Poster presented at: annual Meeting of the Society of General Internal Medicine; April 30-May 3, 2003; Vancouver, Canada
16. Kotseva K, Wood D, De Backer G, et al. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II,and III surveys in eight European countries. Lancet 2009;373:929-40
17. Cowie MR. Simultaneous treatment of hypertension and dyslipidaemia may help to reduce overall cardiovascular risk: focus on amlodipine/atorvastatin single-pill therapy. Int J Clin Pract 2005;Jul59(7):839-46
18. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003;326:1419
19. Zamorano J, Edwards J. Combining antihypertensive and antihyperlipidemic agents-optimizing cardiovascular risk factor management. Integr Blood Press Control 2011;4:55-71
20. Sanz G, Fuster V. Fixed-dose combination therapy and secondary cardiovascular prevention: rationale, selection of drugs and target population. Nat Clin Pract Cardiovasc Med 2009;Feb6(2):101-10
21. Yusuf S, Pais P, Afzal R, et al. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet 2009;373:1341-51
22. Malekzadeh F, Marshall T, Pourshams A, et al. A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors. Int J Clin Pract 2010;64:1220-7
23. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal Results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;Jun13351(9118):1755-62
24. Law MR, Wald NJ, Morris JK, et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003;Jun28 326(7404):1427
25. Gonzalez-Juanatey JR. Mazon Pilar. Prevencion primaria farmacologica en hipertension arterial y dislipemias. Rev Esp Cardiol 2008;61:861-79
26. Pfizer, Inc; Caduet-(amlodipine besylate/atorvastatin calcium) [package insert]. Pfizer, Inc., New York, NY. Available from: http://labeling.pfizer. com/ShowLabeling.aspx?id=531 [Accessed 4 June 2012]
27. Pfizer, Inc; Norvasc-(amlodipine besylate) [package insert]. Pfizer, Inc., New York, NY. Available from: http://media.pfizer.com/files/products/uspi- norvasc.pdf [Accessed 4 June 2012]
28. Murdoch D, Heel RC. Amlodipine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease. Drugs 1991;March 4, 1(3):478-505
29. Pfizer, Inc; Lipitor-(atorvastatin calcium) [package insert]. Pfizer, Inc., New York, NY. Available from: http://www.pfizer.com/files/products/uspi- lipitor.pdf [Accessed 4 June 2012]
30. Mason RP. A rational for combined therapy with a calcium channel blocker and a statin: evaluation of basic and clinical evidence. Curr Drug Targets Cardiovasc Haematol Disord 2005;5(6):489-501
31. Mason RP, Kubant R, Heeba G, et al. Synergistic effect of amlodipine and atorvastatin in reversing LDL-induced endothelial dysfunction. Pharm Res 2008;Aug25(8):1798-806
32. Charbonneau F, Anderson TJ, Title L, et al. Modulation of arterial reactivity using amlodipine and atorvastatin measured by ultrasound examination (MARGAUX). Atherosclerosis 2008;197(1):420-7
33. Ge C-J, Lu S-Z, Chen Y-D, et al. Synergistic effect of amlodipine and atorvastatin on blood pressure, left ventricular remodeling, and C-reactive protein in hypertensive patients with primary hypercholesterolemia. Heart Vessels 2008;23(2):91-5
34. Fogari R, Preti P, Zoppi A, et al. Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients. Eur J Clin Pharmacol 2006;62:817-22
35. Koh KK, Quon MJ, Han SH, et al. Additive beneficial effects of atorvastatin combined with amlodipine in patients with mild to moderate hypertension. Int J Cardiol 2011;146(3):319-25
36. Fogari R, Derosa G, Lazzari P, et al. Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance. Am J Hypertens 2004;17(9):823-7
37. Delsing DJ, Jukema JW, van de Wiel MA, et al. Differential effects of amlodipine and atorvastatin treatment and their combination on atherosclerosis in ApoE*3-Leiden transgenic mice. J Cardiovasc Pharmacol 2003;42(1):63-70
38. Van de Poll SW, Delsing DJ, Wouter Jukema J, et al. Effects of amlodipine, atorvastatin and combination of both on advanced atherosclerotic plaque in APOE*3-Leidentransgenic mice. J Mol Cell Cardiol 2003;35(1):109-18
39. Van de Poll SW, Delsing DJ, Jukema JW, et al. Raman spectroscopic investigation of atorvastatin, amlodipine, and both on atherosclerotic plaque development in APOE*3 Leiden transgenic mice. Atherosclerosis 2002;164(1):65-71
40. Martin-Ventura JL, Munoz-Garcia B, Blanco-Colio LM, et al. Treatment with amlodipine and atorvastatin has additive effect on blood and plaque inflammation in hypertensive patients with carotid atherosclerosis. Kidney Int Suppl 2008(111):S71-4
41. Cohn JN, Wilson DJ, Neutel J, et al. Coadministered amlodipine and atorvastatin produces early improvements in arterial wall compliance in hypertensive patients with dyslipidemia. Am J Hypertens 2009;22(2):137-44
42. Leibovitz E, Beniashvili M, Zimlichman R, et al. Treatment with amlodipine and atorvastatin have additive effect in improvement of arterial compliance in hypertensive hyperlipidemic patients. Am J Hypertens 2003;16(9):715-18
43. Chung M, Calcagni A, Glue P, et al. Bioavailability of amlodipine besylate/atorvastatin calcium combination tablet. J Clin Pharmacol 2006;46(9):1030-7
44. Chung M, Calcagni A, Glue P, et al. Effect of food on the bioavailability of amlodipine besylate/atorvastatin calcium combination tablet. J Clin Pharmacol 2006;46(10):1212-16
45. Bisognano J, McLaughlin T, Roberts CS, et al. Incremental effectiveness of amlodipine besylate in the treatment of hypertension with single and multiple medication regimens. Am J Hypertens 2004;17:676-83
46. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-31
47. ALLHAT investigators. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97
48. Colhoun HM, Betteridge DJ, Durrington PN, et al. on behalf of the CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet 2004;364:685-96
49. Pedersen TR, Faergeman O, Kastelein JJP, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005;294:2437-45
50. LaRosa JC, Grundy SM, Kastelein JJ, et al. Treating to New Targets (TNT) Steering Committee and Investigators. Safety and efficacy of atorvastatin-induced very low-density lipoprotein cholesterol levels in patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study). Am J Cardiol 2007;100:747-52
51. Koren MJ, Hunninghake DB. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the ALLIANCE study. J Am Coll Cardiol 2004;44:1772-9
52. Athyros VG, Papageorgiou AA, Mercouris BR, et al. Treatment with atorvastatin: the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) study. Curr Med Res Opin 2002;18:220-8
53. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001;285:1711-18
54. Rouleau J. Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: Results from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial. Am J Med 2005;118(Suppl 12A):28-35
55. IDEAL-ACS Pedersen TR, Olsson AG, Carter NB, et al. Comparison of the efficacy of intensive atorvastatin versus standard simvastatin therapy in patients with acute coronary syndrome: the IDEAL trial [abstract no. 5015]. 28th Annual Congress of the European Society of Cardiology; 2-6 September 2006; Barcelona, Spain. Eur Heart J 2006. 27(Suppl):856-7
56. Pitt B, Waters D, Brown WV, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med 1999;341:70-6
57. Pasceri V, Patti G, Nusca A, et al. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: Results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2004;110:674-8
58. Patti G, Chello M, Candura D, et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: Results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation 2006;114:1455-61
59. Nissen SE. Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial. Am J Cardiol 2005;96(5A):61F-8F
60. Athyros VG, Kakafika AI, Tziomalos K, et al. Pleiotropic effects of statins-clinical evidence. Curr Pharm Des 2009;15:479-89
61. Messerli FH, Bakris GL, Ferrera D, et al. Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: Results of the AVALON trial. J Clin Hypertens 2006;Aug8(8):571-81
62. Preston RA, Harvey P, Herfert O, et al. A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the Respond trial. J Clin Pharmacol 2007;47:1555-69
63. Neutel JM, Bestermann WH, Dyess EM, et al. The use of a single-pill calcium channel blocker/statin combination in the management of hypertension and dyslipidemia: a randomized, placebo-controlled, multicenter study. J Clin Hypertens 2009;Jan11(1):22-30
64. Pfizer, Inc. A multi-center, randomized study to evaluate efficacy and safety of a fixed combination therapy of amlodipine and atorvastatin in the treatment of concurrent hypertension and hyper-LDL-cholesterolemia [online]. Available from: http://www. clinicalstudyResults.org/documents/company-study- 8859-0.pdf [Accessed 25 November 2009]
65. Blank R, Lasalle J, Reeves R, et al. Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine/atorvastatin Gemini study). J Clin Hypertens 2005;7(5):264-73
66. Erdine S, Ro YM, Tse HF, et al. Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study). J Hum Hypertens 2009;23(3):196-210
67. Flack JM, Victor R, Watson K, et al. Improved attainment of blood pressure and cholesterol goals using singlepill amlodipine/atorvastatin in African Americans: the CAPABLE trial. Mayo Clin Proc 2008;83(1):35-45
68. Hobbs FDR, Gensini G, Mancini GBJ, et al. International open-label studies to assess the efficacy and safety of singlepill amlodipine/atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programme. Eur J Cardiovasc Prev Rehabil 2009;16(4):472-80
69. Zamorano J, Erdine S, Pavia A, et al. Proactive multiple cardiovascular risk factor management compared with usual care in patients with hypertension and additional risk factors: the CRUCIAL trial. Curr Med Res Opin 2011;27(4):821-33
70. Sever PS, Poulter NR, Dahlof B, et al. Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension. J Hypertens 2009;27(5):947-54
71. Zamorano J, Erdine S, Lopez Pavia A, et al. Single-pill amlodipine/atorvastatin versus usual care for cardiovascular risk factor management in patients with diabetes, hypertension and additional risk factors-a CRUCIAL trial subanalysis Presented at The 23rd International Society of Hypertension; Vancouver, Canada 2010
72. Zamorano J, Erdine S, Lopez Pavia A, et al. Single-pill amlodipine/atorvastatin versus usual care for cardiovascular risk factor management in patients aged 65 years or more with hypertension and additional risk factors-a CRUCIAL trial subanalysis 2010. Presented at The 23rd International Society of Hypertension; Vancouver, Canada; 2010
73. Murdoch D, Heel RC. Amlodipine: a Review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease. Drugs 1991;41(3):478-505
74. Newman C, Tsai J, Szarek M, et al. Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. Am J Cardiol 2006;97(1):61-7
75. Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Atorvastatin: safety and tolerability. Expert Opin Drug Saf 2010;9(4):667-74
76. Arca M. Atorvastatin. A safety and tolerability profile. Drugs 2007;67:63-9
77. Escobar C, Echarri R, Barrios V. Relative safety profiles of high dose statin regimens. Vasc Health Risk Manag 2008;4:525-33
78. Athyros VG, Papageorgiou AA, Mercouris BR, et al. Treatment with atorvastatin: the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) study. Curr Med Res Opin 2002;18:220-8
79. Koren MJ, Hunninghake DB. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the ALLIANCE study. J Am Coll Cardiol 2004;44:1772-9
80. Armitage J. The safety of statins in clinical practice. Lancet 2007;370:1781-90
81. US Food and Drug Administration, Center for Drug Evaluation and Research. Statins and hepatotoxicity. [US Food and Drug Administration Web site]. Available from: http://www.fda.gov/Drugs/GuidanceComplianceRegulatory Information/Surveillance/ucm090385. htm [Accessed 4 April 2010]
82. Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovasc Drugs Ther 2005;19:403-14
83. Chang JT, Staffa JA, Parks M, et al. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination. Pharmacoepidemiol Drug Saf 2004;13:417-26
84. Feely WDJ. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 2002;41:343-70
85. MIMS Australia. Caduet: full prescribing information. Sydney (NSW): 2009 Apr 1
86. Amarenco P, Bogousslavsky J, Callahan A, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355:549-59
87. Devabhaktuni M, Bangalore S. Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: patient perspectives. Vasc Health Risk Manag 2009;5(1):377-87
88. Patel BV, Leslie RS, Thiebaud P, et al. Adherence with single-pill amlodipine/atorvastatin vs a two-pill regimen. Vasc Health Risk Manag 2008;4(3):673-81
89. Liew D, Park HJ, Ko SK. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea. Clin Ther 2009;31(10):2189-203
90. Lindgren P, Buxton M, Kahan T, et al. The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: Results from ASCOT1. Pharmacoeconomics 2009;27(3):221-30
91. Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a metaanalysis. Am J Med 2007;120:713-19